Erythroleukemia treated effects of rat plasma profile and erythrocyte membranes.
ALT
AST
Erythrocyte membrane
Erythroleukemia
Plasma cholesterol
Journal
Saudi journal of biological sciences
ISSN: 1319-562X
Titre abrégé: Saudi J Biol Sci
Pays: Saudi Arabia
ID NLM: 101543796
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
15
05
2020
revised:
17
07
2020
accepted:
27
07
2020
entrez:
26
10
2020
pubmed:
27
10
2020
medline:
27
10
2020
Statut:
ppublish
Résumé
Erythroleukemia disease is caused by over production of malignant blood and immature large number of blood cells enters into peripheral compartment. Biophysical and biochemical changes in plasma and erythrocyte membrane in erythroleukemia treated rats were identified. Our study, leukemia is experimentally exposed in rats were injecting erythroleukemia cells (FLC) (H-2d) intravenously in adult rats and normal control rats were maintained. Significant increase in the activity of blood glucose, proteins levels, aspartate transaminase (AST) and alanine transaminase (ALT) values and significant decrease in haemoglobin (Hb), albumin levels in erythroleukemia treated rats were observed when compared with control rats. Cholesterol and low density liproprotein (LDL) levels increased significantly in erythroleukemia treated rats but triglycerides, high density lipoprotein (HDL) and very low density lipoprotein (VLDL) levels decreased significantly. Levels of red cell membrane cholesterol decreased in erythroleukemia treated rats in comparison with control while levels of phospholipids and proteins increased in erythrocytes of erythroleukemia treated rats. Red blood cell (RBC) and white blood cell (WBC) counts increased significantly and platelet count decreased. C/P (cholesterol/phospholipid) ratio decreased significantly in erythroleukemia treated rats. This study has been undertaken for the first time to investigate the effect of (FLC) (H-2d) erythroleukemia cells (treated) in intravenously in adult rats and normal control rats. Results indicate biophysical and biochemical alterations at molecular level in plasma and erythrocyte membrane.
Identifiants
pubmed: 33100851
doi: 10.1016/j.sjbs.2020.07.032
pii: S1319-562X(20)30332-6
pmc: PMC7569129
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2948-2954Informations de copyright
© 2020 The Authors.
Déclaration de conflit d'intérêts
All authors declare that they have no conflict of interest.
Références
Anal Biochem. 1966 Oct;17(1):143-53
pubmed: 4291063
Blood. 2002 Oct 1;100(7):2292-302
pubmed: 12239137
Transfus Med Hemother. 2012 Oct;39(5):353-61
pubmed: 23801928
Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):1943-8
pubmed: 11830646
Arch Biochem Biophys. 1963 Jan;100:119-30
pubmed: 14028302
Clin Chem. 1974 Apr;20(4):470-5
pubmed: 4818200
J Biol Chem. 1951 Nov;193(1):265-75
pubmed: 14907713
J Lab Clin Med. 1953 Mar;41(3):486-92
pubmed: 13035283
Crit Rev Oncol Hematol. 2012 Sep;83(3):303-9
pubmed: 22137828
Blood. 2002 Nov 1;100(9):3135-40
pubmed: 12384410
Recent Prog Horm Res. 1970;26:411-61
pubmed: 4319350
Clin Chim Acta. 1962 Mar;7:199-205
pubmed: 13863676
Periodontol 2000. 1999 Oct;21:84-93
pubmed: 10551176
Blood. 2003 Apr 1;101(7):2895-6
pubmed: 12642345
Annu Rev Med. 1985;36:429-51
pubmed: 2986528
Blood. 1958 Feb;13(2):192-4
pubmed: 13510296
Biochim Biophys Acta. 2000 Dec 15;1535(1):69-77
pubmed: 11113633
Cancer Treat Rev. 2010 Jun;36(4):286-97
pubmed: 20223594
J Exp Med. 1957 Apr 1;105(4):307-18
pubmed: 13416470
Proc Natl Acad Sci U S A. 1966 Jan;55(1):74-81
pubmed: 5220873
Hematology Am Soc Hematol Educ Program. 2008;:374-80
pubmed: 19074113
Biomed Res Int. 2015;2015:682054
pubmed: 25710019
Clin J Am Soc Nephrol. 2011 Mar;6(3):648-55
pubmed: 21071519
Blood. 1969 Nov;34(5):567-72
pubmed: 5260599
Indian J Dent Res. 2013 Jul-Aug;24(4):523
pubmed: 24047855
Clin Chem. 1961 Feb;7:37-53
pubmed: 13695063
Eur J Biochem. 1968 Oct 17;6(1):126-30
pubmed: 4387188
Toxicology. 2003 Aug 1;189(3):223-34
pubmed: 12832155